The appeal of graphene begins with an almost improbable list of properties packed into a sheet of carbon just one atom thick. The material transmits roughly 97.7 percent of visible light, conducts electricity with carrier mobility exceeding 200,000 square centimeters per volt-second at room temperature, and exhibits a Young’s modulus of approximately 1 terapascal with tensile strength above 130 gigapascals. For a contact lens, that combination is extraordinary. A graphene layer can be transparent enough not to disturb vision, conductive enough to carry sensor signals and antenna currents, and mechanically robust enough to survive the relentless deformation of blinking. Unlike brittle transparent conductors such as indium tin oxide, graphene bends and stretches with the soft hydrogel substrates that modern lenses are made from, making it a natural candidate for embedding electronics directly into the ocular environment.

Beyond mechanics and conductivity, graphene brings a biointerface chemistry that the review’s authors highlight as central to its ocular promise. Its ultra-smooth surface topology minimizes protein adsorption and bacterial adhesion, two processes that plague conventional lenses by causing biofouling, discomfort, and infection risk. The material’s inherent antimicrobial activity operates through multiple mechanisms, including direct contact killing, oxidative stress induction, and disruption of bacterial membranes, offering a built-in defense against the microbial colonization that can lead to corneal ulceration and vision loss. Graphene’s aromatic structure and strong covalent bonding also confer resistance to chemical degradation and enzymatic breakdown under physiological conditions, while its naturally hydrophobic surface can be tuned through functionalization to optimize wettability and tear film stability. In principle, these features combine to reduce inflammation, extend safe wearing times, and create surfaces onto which drugs and recognition molecules can be grafted.

The review is careful to sort the literature by technological maturity, distinguishing conceptual device architectures from laboratory proof-of-concept studies and from experimentally demonstrated prototypes, and the differences are striking. At the most speculative end sit the so-called night-vision lenses. Graphene photodetectors on flexible transparent substrates have indeed demonstrated the ability to detect infrared light, converting infrared photons into electrical signals that could in principle be rendered as visible overlays in the wearer’s field of view. The review’s own schematic of such a device is explicitly labeled conceptual, and no integrated wearable lens system with this capability has been clinically validated. Still, the underlying photodetection physics, demonstrated in broadband graphene devices at room temperature, keeps the idea alive for security, defense, and augmented reality applications far beyond medicine.

More grounded are the proof-of-concept demonstrations of electromagnetic shielding and moisture retention. Laboratory studies of lenses coated with an approximately 5-nanometer graphene film reported an 80 percent reduction in microwave-induced protein denaturation, measured through controlled egg-white exposure experiments, alongside a 30 percent reduction in tear evaporation compared with conventional lenses. The dual function addresses two modern anxieties at once: growing exposure to wireless radiation in digital environments and the persistent problem of dry eye among lens wearers. The authors caution that these results represent demonstrations of material functionality rather than established smart lens products, but they illustrate how a single graphene layer can deliver protective properties that conventional hydrogel materials simply cannot match.

At the prototype level, two applications stand out. The first is transparent electroretinography. An experimentally demonstrated graphene-on-lens electrode system covers the full cornea while remaining highly transparent, enabling comprehensive retinal recordings without visual obstruction. In the reported configuration, the graphene electrodes achieved roughly a threefold improvement in signal-to-noise ratio compared with conventional DTL fiber electrodes, a gain the review attributes to the conformal, intimate contact between the atomically thin electrode and the corneal surface, which reduces movement artifacts and permits extended recording sessions without irritation. The second flagship prototype is a wireless intraocular pressure sensor for glaucoma management. Built around graphene nanowall strain gauges with a reported sensitivity of approximately 42,250 parts per million per millimeter of mercury, the lens detects the tiny corneal curvature changes caused by pressure fluctuations and transmits the data wirelessly via a near-field communication antenna. Validation in rabbit eyes demonstrated accurate pressure measurement with minimal tissue response, placing the technology firmly in the preclinical category but marking it as one of the field’s most translationally advanced achievements.

Biosensing extends the vision further into personalized medicine. A proof-of-concept graphene field-effect transistor functionalized with anti-cortisol antibodies has detected tear cortisol at a limit of detection of approximately 10 picograms per milliliter, with smartphone-compatible NFC readout envisioned for routine self-monitoring of stress hormones. Tear-based glucose sensing follows a similar logic, exploiting graphene’s vast surface area and tunable chemistry to immobilize glucose-specific enzymes for non-invasive diabetes surveillance. Drug delivery rounds out the application landscape: graphene oxide laden lenses have been investigated for the controlled release of timolol, cyclosporine, bimatoprost, antibiotics, anti-inflammatory agents, and growth factors, with release profiles that can respond to stimuli such as pH, temperature, or enzymatic activity. By delivering therapeutics directly to ocular tissues, such systems could improve efficacy while minimizing systemic side effects, and graphene’s photodynamic potential, generating reactive oxygen species under light exposure, adds yet another therapeutic modality for treating infections and neovascularization.

Turning these concepts into manufacturable devices is where the field confronts its hardest engineering trade-offs. Chemical vapor deposition produces the highest-quality monolayer graphene, grown on copper foil at around 1000 degrees Celsius in a methane and hydrogen atmosphere, but transferring that fragile film onto a curved, soft lens requires polymer-assisted wet transfer, careful etching, and meticulous rinsing, with costs estimated at roughly five dollars per lens. Solution-phase processing using graphene oxide is cheaper and compatible with existing lens manufacturing, but sacrifices film quality and electrical performance. Patterning strategies, including layer-by-layer assembly, electrochemical deposition, inkjet printing of graphene inks, and direct laser interference patterning at 355 nanometers, allow researchers to write sensors, antennas, and circuits onto curved surfaces, while hydrogel incorporation and microcontact printing embed graphene into the lens bulk. Even the assembly sequence matters: a representative workflow positions a graphene monolayer on a poly(methyl methacrylate) intermediate that serves as both transfer scaffold and dielectric buffer before final cast-molding into pHEMA hydrogel at 70 degrees Celsius.

Safety and regulatory hurdles may prove even more formidable than the engineering. Graphene’s impermeability, so useful for moisture retention, threatens to choke off the oxygen transmission that corneal health demands, prompting proposed solutions such as focused ion beam or laser drilling of 50-nanometer pores to restore permeability above 30 barrer. Heat dissipation is another concern, with temperature rises of 2 to 3 degrees Celsius observed under 2.4 gigahertz exposure, motivating micro-heat-spreader grids beneath the graphene layer. Delamination after roughly 30 days of wear, driven by weak graphene-hydrogel adhesion under the mechanical stress of blinking, may be addressed by silanizing the lens surface with 3-aminopropyl-triethoxysilane to create covalent bonds. More fundamentally, the toxicology remains unsettled: pristine graphene generally shows low short-term cytotoxicity toward corneal cells, but graphene oxide can induce oxidative stress and membrane damage, some studies report DNA strand breaks and mitochondrial damage in human corneal epithelial cell lines under prolonged exposure, and tear film enzymes such as peroxidases and lysozymes may partially degrade functionalized graphene into bioactive products whose in vivo toxicity is largely uncharacterized. No longitudinal human trials of embedded graphene lenses exist, and no graphene-enhanced contact lens has yet received regulatory approval, although the FDA and EMA have issued draft guidelines for nanomaterials in medical devices.

The review’s authors close with a sober but optimistic outlook for 2025 to 2030. Future platforms may combine graphene with other two-dimensional materials such as molybdenum disulfide or hexagonal boron nitride to build heterostructures capable of multimodal biosensing of glucose, lactate, cytokines, and cortisol, while micro-scale graphene supercapacitors and energy-harvesting modules could free lenses from external power, and artificial intelligence could interpret sensor signals in real time on the lens itself. Modular designs with interchangeable sensing and therapeutic units, harmonized ISO testing protocols for nanoparticle shedding and chronic exposure, and roll-to-roll manufacturing on copper-nickel foils to slash costs all feature in the proposed roadmap. For now, the authors conclude, graphene-based contact lenses remain a promising but technically and translationally immature technology, one whose success will be decided not only in the materials laboratory but in standardized toxicology, scalable manufacturing, and the slow, exacting work of proving that a sheet of carbon one atom thick can live safely on the human eye for years at a time.

Subject of Research: Graphene-integrated contact lenses for ocular biosensing, drug delivery, and antimicrobial protection

Article Title: Graphene-integrated contact lenses for ocular sensing, drug delivery, and antimicrobial protection

Article References: Shaker, L. M., Alamiery, A., & Hussien, N. A. (2026). Graphene-integrated contact lenses for ocular sensing, drug delivery, and antimicrobial protection. Discover Chemistry, 3(1), Article 481. https://doi.org/10.1007/s44371-026-00894-0

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00894-0

Keywords: graphene, contact lenses, smart lenses, biosensors, drug delivery, antimicrobial, intraocular pressure, glaucoma, electroretinography, biocompatibility, chemical vapor deposition, wearable electronics